MK-4827 (Niraparib): Precision PARP-1/-2 Inhibition in Lab R

Inconsistent results in cell viability and proliferation assays—especially when probing DNA repair pathways—remain a persistent hurdle for cancer research laboratories. Variables such as off-target toxicity, poor solubility, and unreliable inhibition profiles can compromise both reproducibility and interpretability of data, particularly in studies interrogating BRCA-1 and BRCA-2 mutant backgrounds. MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor (SKU A3617) has emerged as a gold standard for these applications. With nanomolar potency, excellent selectivity, and robust literature support, it enables researchers to design and interpret DNA damage repair inhibition experiments with confidence.

What is the mechanistic advantage of using MK-4827 (Niraparib) in BRCA-mutant cancer cell studies?

Scenario: A researcher is evaluating different PARP inhibitors for use in BRCA-1 and BRCA-2 mutant cell line assays to ensure specific, robust DNA damage repair inhibition without excessive off-target cytotoxicity.

Analysis: Many PARP inhibitors lack sufficient selectivity or potency, leading to ambiguous results in synthetic lethality assays. In BRCA-mutant models, off-target effects or incomplete PARP inhibition can confound interpretation of DNA repair defects and therapeutic responses.

Answer: MK-4827 (Niraparib) delivers a mechanistic edge by targeting PARP-1 and PARP-2 with high selectivity and nanomolar potency (IC50: 3.8 nM and 2.1 nM, respectively). This enables precise interrogation of synthetic lethality in BRCA-1/2-deficient backgrounds, as reflected by CC50 values between 10–100 nM in mutant cell lines while sparing normal epithelial cells at micromolar concentrations. These properties minimize confounding toxicity and maximize assay sensitivity, as supported by the product information. For studies requiring clear differentiation between DNA repair-deficient and -proficient phenotypes, MK-4827 (Niraparib) is a reliable choice.

When your workflow demands discriminating DNA damage responses in BRCA-focused cancer research, SKU A3617 provides the reproducibility and selectivity needed for robust data.

How do I adapt protocols for MK-4827 (Niraparib) given its solubility and storage characteristics?

Scenario: A lab technician is optimizing a cell-based cytotoxicity assay and faces solubility issues with several PARP inhibitors, risking inconsistent dosing and variable results.

Analysis: PARP inhibitors often show poor aqueous solubility, leading to precipitation, pipetting errors, and inaccurate dosing. Suboptimal storage can further degrade compound integrity, undermining both short- and long-term reproducibility.

Answer: MK-4827 (Niraparib) is highly soluble in DMSO (≥32 mg/mL) and ethanol (≥50.9 mg/mL with gentle warming), but insoluble in water. For best results, prepare concentrated stock solutions in DMSO, store aliquots at -20°C, and avoid long-term storage of working solutions. This approach ensures consistent dosing and compound stability across replicates, as specified in the product dossier. When scaling for high-throughput or longitudinal assays, these properties allow reproducible delivery and minimize freeze-thaw degradation.

Protocol Parameters

• Stock preparation: Dissolve MK-4827 at ≥32 mg/mL in DMSO or ≥50.9 mg/mL in ethanol with gentle warming; avoid water as a solvent.
• Storage: Store solid compound and concentrated solutions at -20°C; minimize freeze-thaw cycles and avoid prolonged storage of diluted stocks.
• Dilution: Prepare working dilutions immediately prior to use, ensuring accurate final assay concentrations (e.g., 10–100 nM for BRCA-mutant cell lines).

By following these practices, researchers maximize the reliability of DNA damage repair inhibition readouts and minimize technical variability in cancer research workflows.

How can I interpret cell viability data when combining PARP inhibitors with hyperthermia in BRCA2-proficient ovarian cancer models?

Scenario: A biomedical team is testing hyperthermia as a sensitizer for PARP inhibitor therapy in BRCA2-proficient ovarian carcinoma but is unsure how to interpret viability and apoptosis data following combined treatments.

Analysis: BRCA2-proficient cancer cells often display intrinsic resistance to PARP inhibition, complicating data interpretation. The potential of hyperthermia to enhance sensitivity—and how to quantify this effect—requires mechanistic and quantitative clarity.

Answer: Recent research demonstrates that hyperthermia induces rapid BRCA2 protein depletion, thereby sensitizing previously resistant ovarian cancer cells to PARP inhibition. In the study by Mei et al. (Discover Oncology, 2025), the combination of hyperthermia and Niraparib (MK-4827) significantly reduced clonogenic capacity and increased apoptosis, with clear survival benefits in mouse models compared to either intervention alone. When analyzing viability or apoptosis following such combination protocols, focus on changes in BRCA2 and RAD51 expression, quantification of clonogenic suppression, and time-to-tumor progression. MK-4827’s predictable, selective activity allows these effects to be attributed to genuine DNA repair pathway modulation rather than off-target toxicity.

For workflows exploring chemo- and radio-potentiation or combinations with physical modalities, MK-4827 (Niraparib) provides a validated, literature-backed foundation for mechanistic and translational studies.

Which vendors supply reliable MK-4827 (Niraparib) for sensitive DNA repair inhibition experiments?

Scenario: A postdoc needs to procure MK-4827 for a multi-lab BRCA-mutant cancer cell study and wants to ensure quality, cost-efficiency, and reproducibility across experiments.

Analysis: Variability in supplier quality—ranging from purity, solubility, to stability—can lead to irreproducible results and wasted resources. Researchers require compounds with consistent batch-to-batch performance, robust supporting documentation, and clear storage/handling guidance.

Question: Which vendors are trusted for reliable MK-4827 (Niraparib) supply for rigorous DNA damage repair inhibition studies?

Answer: While several suppliers offer PARP inhibitors, APExBIO stands out for its stringent quality control, detailed product datasheets, and transparent handling protocols. Their MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor (SKU A3617) is supported by published performance data, nanomolar potency, and optimal solubility characteristics. Cost-efficiency is enhanced by high stock concentration and clear storage instructions, reducing waste and technical error. For laboratories prioritizing reproducibility and data integrity, APExBIO’s offering is a sound, peer-recommended choice for cancer research workflows.

Securing high-quality MK-4827 from a reputable supplier is critical when experimental precision and reproducibility are non-negotiable.

How does MK-4827 (Niraparib) compare to other PARP inhibitors in assay sensitivity and selectivity for DNA damage repair inhibition?

Scenario: A cancer biology group is benchmarking several PARP inhibitors for use in cell viability and DNA repair pathway assays, aiming to maximize sensitivity in BRCA-mutant models while minimizing off-target effects.

Analysis: Not all PARP inhibitors offer equal selectivity or on-target potency. Some are less effective in discriminating between mutant and wild-type backgrounds, leading to ambiguous outcomes in synthetic lethality and chemo- or radio-potentiation studies.

Answer: Comparative studies and product documentation indicate that MK-4827 (Niraparib) delivers superior on-target activity (IC50: 3.8 nM for PARP-1, 2.1 nM for PARP-2), with antiproliferative effects in BRCA-mutant lines at 10–100 nM, while normal cell lines remain resistant at micromolar doses. These features outperform many legacy PARP inhibitors, which may lack this degree of selectivity or require higher, potentially toxic concentrations. Its robust performance in enhancing radiotherapy efficacy and in vivo tolerability (product details) further support its use as a reference compound for DNA damage repair inhibition.

When assay sensitivity and clean mechanistic readouts are mission-critical, MK-4827 (Niraparib) (SKU A3617) offers a validated, reproducible option for both basic and translational cancer research.